Literature DB >> 29330758

[Monoclonal gammopathy of undetermined significance and multiple myeloma].

M Schmalzing1, H-P Tony2, S Knop2.   

Abstract

In rheumatological practice monoclonal gammopathy of undetermined significance (MGUS) is a common incidental finding. Several rheumatic inflammatory diseases are known to have an elevated risk of MGUS, which can evolve into multiple myeloma or other lymphatic malignancies. The relevant definitions of disease entities are described, as well as algorithms for further diagnostic work-up and follow-up for monoclonal gammopathy, depending on the risk of progression. Therapeutic strategies against multiple myeloma are presented. Some of these therapeutic modalities could play a future role in treating plasma cell-dominated autoimmune diseases.

Entities:  

Keywords:  Disease-modifying antirheumatic drugs; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Rheumatoid arthritis; Sjögren’s syndrome

Mesh:

Year:  2017        PMID: 29330758     DOI: 10.1007/s00393-017-0335-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  19 in total

1.  Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment.

Authors:  F Prignano; L Pescitelli; F Ricceri; A Ermini; T Lotti
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-08-11       Impact factor: 6.166

2.  Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a cross-sectional study.

Authors:  V Di Lernia; E Ficarelli; A Lallas; N Possemato; I Chiarolanza; C Salvarani
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-06-09       Impact factor: 6.166

3.  Myeloma today: Disease definitions and treatment advances.

Authors:  Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-05-11       Impact factor: 10.047

4.  Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment.

Authors:  Apostolia Maria Tsimberidou; Tracey Waddelow; Hagop M Kantarjian; Maher Albitar; Francis J Giles
Journal:  Leuk Res       Date:  2003-05       Impact factor: 3.156

5.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

6.  Successful treatment of a patient with rheumatoid arthritis and IgA-κ multiple myeloma with tocilizumab.

Authors:  Yasushi Matsuyama; Takao Nagashima; Kyoko Honne; Yasuyuki Kamata; Masahiro Iwamoto; Hitoaki Okazaki; Kazuya Sato; Keiya Ozawa; Seiji Minota
Journal:  Intern Med       Date:  2011-03-15       Impact factor: 1.271

7.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

8.  Monoclonal gammopathy in systemic lupus erythematosus.

Authors:  Y M Ali; M B Urowitz; D Ibanez; D D Gladman
Journal:  Lupus       Date:  2007       Impact factor: 2.911

9.  Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome.

Authors:  Anne-Laurence Tomi; Rakiba Belkhir; Gaétane Nocturne; Frédéric Desmoulins; Elisabeth Berge; Stephan Pavy; Corinne Miceli-Richard; Xavier Mariette; Raphaèle Seror
Journal:  Arthritis Rheumatol       Date:  2016-05       Impact factor: 10.995

10.  History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Ebba K Lindqvist; Ola Landgren; Sigrún H Lund; Ingemar Turesson; Malin Hultcrantz; Lynn Goldin; Magnus Björkholm; Sigurdur Y Kristinsson
Journal:  Ann Hematol       Date:  2016-11-02       Impact factor: 3.673

View more
  1 in total

1.  Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.

Authors:  Normann Steiner; Georg Göbel; Daniela Michaeler; Anna-Luise Platz; Wolfgang Prokop; Anna Maria Wolf; Dominik Wolf; Christina Duftner; Eberhard Gunsilius
Journal:  Blood Adv       Date:  2021-03-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.